keyword
MENU ▼
Read by QxMD icon Read
search

faecal calprotectin in ulcerative colitis

keyword
https://www.readbyqxmd.com/read/29121178/exploration-of-predictive-biomarkers-of-early-infliximab-response-in-acute-severe-colitis-a-prospective-pilot-study
#1
Lauren Beswick, Ourania Rosella, Gennaro Rosella, Belinda Headon, Miles P Sparrow, Peter R Gibson, Daniel R van Langenberg
Background: Outcomes of acute severe ulcerative colitis (ASUC) appear dependent on early intervention with the first and/or further infliximab(IFX) doses, though parameters to guide decision-making remain uncertain. Aim: To assess whether serum/faecal IFX levels and inflammatory biomarkers early post-IFX dose can predict ASUC outcomes. Methods: This prospective pilot study consecutively recruited inpatients with steroid-refractory ASUC, who then received 1-3 IFX rescue doses (5mg/kg/dose) per treating clinician's discretion...
November 7, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28932267/clinical-performance-of-an-infliximab-rapid-quantification-assay
#2
Fernando Magro, Joana Afonso, Susana Lopes, Rosa Coelho, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Tânia Meira, Patrícia Andrade, João-Bruno Soares, Diana Carvalho, Paula Sousa, Ana Isabel Vieira, Joanne Lopes, Cláudia Camila Dias, Karel Geboes, Fátima Carneiro
BACKGROUND: Therapeutic drug monitoring (TDM)-based algorithms can be used to guide infliximab (IFX) adjustments in inflammatory bowel disease (IBD) patients. This study aimed to explore a rapid IFX-quantification test from a clinical perspective. METHODS: This manuscript describes a prospective cohort study involving 110 ulcerative colitis (UC) patients on the maintenance phase of IFX. IFX trough levels were quantified using a rapid quantification assay and a commonly-used reference kit...
September 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28881876/accuracy-of-faecal-immunochemical-test-to-predict-endoscopic-and-histological-healing-in-ulcerative-colitis-a-prospective-study-based-on-validated-histological-scores
#3
Hai Yun Shi, Francis K L Chan, Anthony W H Chan, Akira Higashimori, Moe Kyaw, Jessica Y L Ching, Arthur K C Luk, Sunny H Wong, Justin C Y Wu, Joseph J Y Sung, Siew C Ng
Background and Aims: Endoscopic and histological healing are associated with improved clinical outcomes in ulcerative colitis [UC]. We aimed to investigate the predictive value of faecal immunochemical test [FIT] for endoscopic and histological healing in UC. Methods: We measured quantitative FIT and faecal calprotectin [FC] in 140 consecutive UC patients who underwent colonoscopy. We assessed the diagnostic accuracy of FIT for predicting endoscopic healing using the Mayo endoscopic subscore [MES 0/1] and for histological healing using the Geboes score [< 2...
September 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28844038/unrestricted-faecal-calprotectin-testing-performs-poorly-in-the-diagnosis-of-inflammatory-bowel-disease-in-patients-in-primary-care
#4
Samantha Conroy, Melissa F Hale, Simon S Cross, Kirsty Swallow, Reena H Sidhu, Ravishankar Sargur, Alan J Lobo
BACKGROUND: Faecal calprotectin (FC) measurement distinguishes patients with inflammatory bowel disease (IBD) from those with irritable bowel syndrome but evidence of its performance in primary care is limited. AIMS: To assess the yield of IBD from FC testing in primary care. METHODS: Retrospective review of hospital records to assess the outcome following FC testing in primary care. Investigations for all patients undergoing FC testing in a single laboratory for 6 months from 1 October 2013 to 28 February 2014 were reviewed...
August 26, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28815032/pain-may-be-an-important-factor-to-consider-in-inflammatory-bowel-disease-patients-troubled-by-fatigue
#5
Lars-Petter Jelsness-Jørgensen, Svein-Oskar Frigstad, Bjørn Moum, Tore Grimstad, Randi Opheim, Jørgen Jahnsen, Tomm Bernklev
BACKGROUND: Pain has been associated with fatigue in many chronic diseases, but data are not available for inflammatory bowel disease (IBD). The aim of this study was to investigate whether fatigue is associated with pain in IBD after adjusting for the relevant covariates. METHODS: Participants were recruited from nine hospitals in the south-eastern and western part of Norway. Socio-demographic variables were self-reported by patients. Disease activity was assessed by disease activity indices and faecal calprotectin...
August 2017: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/28790099/gsk2586184-a-jak1-selective-inhibitor-in-two-patients-with-ulcerative-colitis
#6
Leonie C S De Vries, Valerie J Ludbrook, Kirsty J Hicks, Geert R D'Haens
Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC). Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Adverse events including neutropenia and anaemia resulting from JAK2 inhibition have been observed in actively treated patients. By selectively targeting JAK1, such adverse events could be expected to be avoided. This open label study was designed to enrol 15 patients with UC, however the trial was discontinued after two inclusions due to safety concerns with the agent in a parallel trial for systemic lupus erythematosus...
August 7, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28735301/effect-of-faecal-calprotectin-assay-variability-on-the-management-of-inflammatory-bowel-disease-and-potential-role-of-faecal-s100a12
#7
Simon John Whitehead, Clare Ford, Rousseau Mariano Gama, Ala Ali, Brian McKaig, Jenna Louise Waldron, Helen Steed, Matthew James Brookes
AIMS: To prospectively evaluate whether between-assay variability of different faecal calprotectin (f-Cp) assays influences diagnostic accuracy for inflammatory bowel disease (IBD) in a cohort of patients with confirmed IBD and irritable bowel syndrome (IBS). To also evaluate the diagnostic accuracy of faecal S100A12 (f-S100A12) against f-Cp in the same patient cohort and assess whether f-S100A12 offers additional diagnostic value. METHODS: F-Cp using four commercially available f-Cp assays, f-S100A12 and blood biomarkers were measured in patients, recruited from the local IBD clinic, who had established IBS or active ulcerative colitis (UC) and Crohn's disease (CD)...
July 22, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28651829/evaluation-of-a-12-week-targeted-vitamin-d-supplementation-regimen-in-patients-with-active-inflammatory-bowel-disease
#8
Mayur Garg, Ourania Rosella, Gennaro Rosella, Yunqiu Wu, John S Lubel, Peter R Gibson
BACKGROUND & AIMS: Vitamin D at serum 25(OH)D concentrations above 100 nmol/L is associated with disease remission in patients with IBD, suggesting targeted dosing might be anti-inflammatory. This study aimed to assess the effectiveness, safety and predictors of a 12-week regimen of vitamin D supplementation to achieve such a target in patients with active disease. METHODS: In a pilot study, patients with active colitis and a serum 25(OH)D concentration <75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100-125 nmol/L...
June 15, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28618062/examining-maintenance-care-following-infliximab-salvage-therapy-for-acute-severe-ulcerative-colitis
#9
Dean Seah, Matthew C Choy, Alexandra Gorelik, William R Connell, Miles P Sparrow, Daniel van Langenberg, Geoffrey Hebbard, Gregory Moore, Peter De Cruz
BACKGROUND AND AIMS: Data supporting the optimal maintenance drug therapy & strategy to monitor ongoing response following successful infliximab (IFX) induction, for acute severe ulcerative colitis (ASUC), are limited. We aimed to evaluate maintenance & monitoring strategies employed in patients post IFX induction therapy. METHODS: Patients in 6 Australian tertiary centres treated with IFX for steroid-refractory ASUC between April 2014 & May 2015 were identified via hospital IBD & pharmacy databases...
June 15, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28362144/long-term-effectiveness-of-vedolizumab-in-inflammatory-bowel-disease-a-national-study-based-on-the-swedish-national-quality-registry-for-inflammatory-bowel-disease-swibreg
#10
Carl Eriksson, Jan Marsal, Daniel Bergemalm, Lina Vigren, Jan Björk, Michael Eberhardson, Pontus Karling, Charlotte Söderman, Pär Myrelid, Yang Cao, Daniel Sjöberg, Mari Thörn, Per Karlén, Erik Hertervig, Hans Strid, Jonas F Ludvigsson, Sven Almer, Jonas Halfvarson
OBJECTIVES: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness. MATERIALS AND METHODS: Patients initiating vedolizumab between 1 June 2014 and 30 May 2015 were identified through the Swedish National Quality Registry for IBD. Prospectively collected data on treatment and disease activity were extracted...
June 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28333288/exposure-efficacy-relationships-for-vedolizumab-induction-therapy-in-patients-with-ulcerative-colitis-or-crohn-s-disease
#11
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Huyuan Yang, Silvio Danese, Jean-Frédéric Colombel, Michael Smyth, William J Sandborn, Brian G Feagan, Walter Reinisch, Bruce E Sands, Miguel Sans, Irving Fox
Background and Aims: A positive relationship between vedolizumab trough serum concentrations and clinical outcomes in patients with ulcerative colitis [UC] or Crohn's disease [CD] has been reported. Here we further explore exposure-efficacy relationships for vedolizumab induction therapy in post hoc analyses of GEMINI study data. Methods: Vedolizumab trough concentrations at Week 6 or 10 were grouped in quartiles and clinical outcome rates calculated. Exposure-efficacy relationships at Week 6 and potential baseline covariate effects were explored using logistic regression and individual predicted cumulative average concentration through Week 6 [Caverage] as exposure measure...
August 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28239876/the-potential-of-volatile-organic-compounds-for-the-detection-of-active-disease-in-patients-with-ulcerative-colitis
#12
A Smolinska, A G L Bodelier, J W Dallinga, A A M Masclee, D M Jonkers, F-J van Schooten, M J Pierik
BACKGROUND: To optimise treatment of ulcerative colitis (UC), patients need repeated assessment of mucosal inflammation. Current non-invasive biomarkers and clinical activity indices do not accurately reflect disease activity in all patients and cannot discriminate UC from non-UC colitis. Volatile organic compounds (VOCs) in exhaled air could be predictive of active disease or remission in Crohn's disease. AIM: To investigate whether VOCs are able to differentiate between active UC, UC in remission and non-UC colitis...
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28203278/efficacy-of-granulocyte-and-monocyte-apheresis-for-antibiotic-refractory-pouchitis-after-proctocolectomy-for-ulcerative-colitis-an-open-label-prospective-multicentre-study
#13
Takayuki Yamamoto, Toshiaki Tanaka, Tadashi Yokoyama, Takahiro Shimoyama, Hiroki Ikeuchi, Motoi Uchino, Toshiaki Watanabe
BACKGROUND: Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospective study was to evaluate the efficacy of GMA for antibiotic-refractory pouchitis after proctocolectomy for UC. METHODS: A total of 13 patients with pouchitis disease activity index (PDAI) > 7 unresponsive to 2 weeks of antibiotic therapy were included...
February 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28138990/raised-faecal-calprotectin-is-associated-with-subsequent-symptomatic-relapse-in-children-and-adolescents-with-inflammatory-bowel-disease-in-clinical-remission
#14
K Diederen, D R Hoekman, A Leek, V M Wolters, T Z Hummel, T G de Meij, B G P Koot, M M Tabbers, M A Benninga, A Kindermann
BACKGROUND: Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM: To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS: In this cross-sectional cohort study, patients <18 years with Crohn's disease or ulcerative colitis in clinical remission ≥3 months were included. At baseline, clinical and biochemical disease activity were assessed using the abbreviated-Pediatric Crohn's Disease Activity Index or Pediatric Ulcerative Colitis Activity Index, and FC and CRP respectively...
April 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27941189/clinical-evaluation-of-children-with-ulcerative-colitis-treated-between-2013-2015-own-experience
#15
Monika Meglicka, Michał Szczepański, Maciej Dądalski, Jarosław Kierkuś
AIM: Evaluation of the changes in the endoscopic, laboratory and clinical status in children with ulcerative colitis (UC) with regard to the duration of the disease. MATERIAL AND METHODS: 91 children with UC were involved in the study. Each of them had colonoscopy and their laboratory values were tested. We assessed the colonoscopy results by the Paris classification and by the Baron score. Moreover, demographic, clinical and anthropometric data were collected. We divided our patients into five subgroups depending on the duration of the disease...
2016: Developmental Period Medicine
https://www.readbyqxmd.com/read/27881072/patients-with-longstanding-ulcerative-colitis-in-remission-do-not-have-more-irritable-bowel-syndrome-like-symptoms-than-controls
#16
D Lundgren, J Rutegård, V Eklöf, R Palmqvist, P Karling
BACKGROUND: Irritable bowel syndrome (IBS) is more common in patients with ulcerative colitis (UC) than expected. The prevalence of IBS in patients with UC with longstanding disease is not known. We investigated the prevalence of IBS-like symptoms in patients with UC in remission and longstanding disease in comparison to control subjects. METHODS: Sixty-eight patients with UC and 33 patients with hereditary familiar colon cancer and who underwent colonoscopy surveillance were included...
November 24, 2016: BMC Gastroenterology
https://www.readbyqxmd.com/read/27856523/beyond-histological-remission-intramucosal-calprotectin-as-a-potential-predictor-of-outcomes-in-ulcerative-colitis
#17
Marianne Guirgis, Emily Wendt, Lai Mun Wang, Alissa Walsh, Daniel Burger, Robert V Bryant, Alex Kent, Rebecca Adamson, Oliver Brain, Simon P L Travis, Satish Keshav
Background and Aims: Histological remission and low faecal calprotectin are positive prognostic factors in ulcerative colitis [UC]. Intramucosal calprotectin [iMC], which can be readily determined by immunohistochemistry, has not so far been evaluated as a predictor of outcome in UC. We aimed to investigate the relationship between iMC and clinical, endoscopic, and histological measures of remission in UC, and the independent prognostic value of iMC. Methods: Ambulant patients with UC were recruited for a study comparing clinical activity indices...
April 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27722996/effectiveness-of-adalimumab-for-the-treatment-of-ulcerative-colitis-in-clinical-practice-comparison-between-anti-tumour-necrosis-factor-na%C3%A3-ve-and-non-na%C3%A3-ve-patients
#18
Marisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, Alicia López-García, Valle García-Sánchez, Antonio López-Sanromán, Esther Hinojosa, Lucía Márquez, Santiago García-López, María Chaparro, Montserrat Aceituno, Margalida Calafat, Jordi Guardiola, Blanca Belloc, Yolanda Ber, Luis Bujanda, Belén Beltrán, Cristina Rodríguez-Gutiérrez, Jesús Barrio, José Luis Cabriada, Montserrat Rivero, Raquel Camargo, Manuel van Domselaar, Albert Villoria, Hugo Salata Schuterman, David Hervás, Pilar Nos
BACKGROUND: Ulcerative colitis (UC) treatment is focused to achieve mucosal healing, avoiding disease progression. The study aimed to evaluate the real-world effectiveness of adalimumab (ADA) in UC and to identify predictors of remission to ADA. METHODS: This cohort study used data from the ENEIDA registry. Clinical response, clinical remission, endoscopic remission, adverse events (AE), colectomy, and hospitalisations were evaluated; baseline characteristics and biological parameters were compared to determine predictors of response...
July 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27714831/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active-inflammatory-bowel-disease-a-prospective-multicenter-observational-study
#19
MULTICENTER STUDY
A Stallmach, C Langbein, R Atreya, T Bruns, A Dignass, K Ende, J Hampe, F Hartmann, M F Neurath, J Maul, J C Preiss, R Schmelz, B Siegmund, H Schulze, N Teich, U von Arnim, D C Baumgart, C Schmidt
BACKGROUND: Vedolizumab, a monoclonal antibody targeting the α4β7-integrin, is effective in inducing and maintaining clinical remission in Crohn's disease and ulcerative colitis according to randomised clinical trials. AIM: To determine the long-term effectiveness of vedolizumab in a real-world clinical setting. METHODS: This observational registry assessed the clinical outcome in patients treated with vedolizumab for clinically active Crohn's disease (n = 67) or ulcerative colitis (n = 60)...
December 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27699005/calprotectin-as-a-diagnostic-tool-for-inflammatory-bowel-diseases
#20
Marianthi Chatzikonstantinou, Panagiotis Konstantopoulos, Spyros Stergiopoulos, Konstantinos Kontzoglou, Christos Verikokos, Despina Perrea, Dimitris Dimitroulis
Inflammatory bowel diseases (IBD) are chronic intestinal disorders caused by a number of factors, including external influences, intestinal microbiota and genetics. The two major clinically defined types of IBD are Crohn's disease and ulcerative colitis, each of which is characterized by relapses in the clinical course, thus patients must be under constant observation via regular endoscopies. As endoscopy, which has been used for direct evaluation and diagnosis of IBD, requires uncomfortable and expensive bowel preparation, a non-invasive test was required to reduce the number of patients undergoing unnecessary endoscopy...
October 2016: Biomedical Reports
keyword
keyword
48306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"